Bayer: Supreme Court appeal status and Philadelphia verdict impact on liability provisions 2026

Supreme Court Docket 2026: The Durnell Certiorari Grant Analysis

The United States Supreme Court issued a decisive order on January 16, 2026, granting certiorari in *Monsanto Co. v. Durnell* (Docket No. 24-1068). This move places the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preemption defense at the center of the judicial calendar. The Court examine whether federal law bars state-level failure-to-warn claims when the Environmental Protection Agency (EPA) has expressly approved a pesticide label without a cancer warning. Oral arguments are scheduled for April 27, 2026. This intervention follows a chaotic 24-month period of conflicting appellate rulings and volatility in state courts, particularly in Philadelphia. The catalyst for the Court’s review is the circuit split crystallized by the Third Circuit’s August 2024 ruling in *Schaffner v. Monsanto*, which held that FIFRA preempts state claims. This decision stands in direct opposition to rulings from the Ninth and Eleventh Circuits, as well as the Missouri Court of Appeals in *Durnell*.

The Solicitor General’s Pivot

A serious factor in the Court’s decision to hear the case was the reversal of position by the U. S. Solicitor General. On December 1, 2025, Solicitor General D. John Sauer filed an amicus brief urging the Court to grant review and rule in favor of Bayer. The brief argued that allowing 50 different state labeling regimes to override EPA scientific determinations undermines federal authority. This marks a departure from the government’s 2022 stance, which recommended against review in *Hardeman*.

Philadelphia Verdicts: The Liability Pressure Cooker

While *Durnell* originated in Missouri, the litigation were heavily influenced by the Philadelphia Court of Common Pleas. Throughout 2024 and 2025, this venue produced a series of high-value verdicts that accelerated Bayer’s liability exposure. The “McKivison” verdict in January 2024, initially $2. 25 billion, was later reduced to $400 million yet signaled the severe financial risks of the Philadelphia docket. The between the federal Third Circuit (*Schaffner*) and Pennsylvania state courts created an untenable legal environment where federal claims in Pennsylvania were preempted, while identical state claims in Philadelphia resulted in nine-figure awards.

Financial and Settlement Strategy

In direct response to the *Durnell* grant and the ongoing Philadelphia litigation, Bayer announced a strategic shift on February 17, 2026. The company proposed a new $7. 25 billion class settlement method designed to resolve current and future claims. This proposal is contingent on the Supreme Court’s ruling. The company also adjusted its financial provisions. In its 2025 Annual Report, released March 4, 2026, Bayer increased its litigation provisions from €7. 8 billion to €11. 8 billion. This 51% increase reflects the dual reality of the *Schaffner* victory offering a legal shield and the Philadelphia verdicts exposing continued jury risk.

“The Supreme Court decision to take the case is good news for U. S. farmers who need regulatory clarity. It is also an important step in our multi-pronged strategy to significantly contain this litigation.”
, Bill Anderson, CEO of Bayer AG (January 16, 2026)

The Preemption Argument in Durnell

The central legal question in *Durnell* is whether a state jury can penalize a company for failing to include a warning that the EPA has explicitly rejected. Bayer that because the EPA has consistently classified glyphosate as “not likely to be carcinogenic” and prohibits a cancer warning on the label, complying with a state-law duty to warn would force the company to violate federal misbranding laws. The Third Circuit accepted this “impossibility preemption” argument in *Schaffner*. The court found that Pennsylvania’s requirement for a cancer warning was “different from” and ” to” the federal requirement, thus violating FIFRA’s uniformity clause. The Supreme Court’s ruling in *Durnell* determine if this logic applies nationwide, chance extinguishing tens of thousands of pending cases.

The Schaffner Precedent: Third Circuit Federal Preemption Ruling

On August 15, 2024, the United States Court of Appeals for the Third Circuit issued a decisive ruling in Schaffner v. Monsanto Corp. that fundamentally altered the legal for Bayer’s glyphosate litigation. The court held that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts Pennsylvania state law failure-to-warn claims. The panel reasoned that because the Environmental Protection Agency (EPA) approved the Roundup label without a cancer warning, and in fact prohibited such a warning, a state-law requirement to include one would impose a labeling requirement ” to or different from” federal mandates.

This decision created a direct circuit split with the Ninth Circuit’s ruling in Hardeman v. Monsanto and the Eleventh Circuit’s decision in Carson v. Monsanto, both of which had previously rejected preemption arguments. The Schaffner ruling provided Bayer with the conflicting appellate authority necessary to force a review by the United States Supreme Court.

Supreme Court Appeal Status: Monsanto v. Durnell

Following the Schaffner split, Bayer petitioned the Supreme Court for certiorari in the case of Monsanto Company v. John L. Durnell (No. 24-1068), using the Missouri state court case as the vehicle to address the federal preemption question. The timeline of the appeal is as follows:

The specific question presented to the Court is: “Whether the Federal Insecticide, Fungicide, and Rodenticide Act preempts a label-based failure-to-warn claim where EPA has not required the warning.” A ruling in Bayer’s favor would theoretically nullify the failure-to-warn claims that underpin the vast majority of pending Roundup lawsuits.

Impact on Philadelphia Court of Common Pleas Verdicts

While the Schaffner ruling governs federal courts in Pennsylvania, the Philadelphia Court of Common Pleas (a state court system) has continued to process trials, resulting in significant volatility for Bayer. State courts are not strictly bound by the Third Circuit’s interpretation of federal preemption until the U. S. Supreme Court problem a controlling decision. Consequently, juries in Philadelphia have delivered massive verdicts even after the Schaffner decision was handed down.

“The jury’s punitive damages award sends a clear message that this multi-national corporation needs top to bottom change.” , Statement from attorneys representing plaintiff John McKivison, January 2024.

Recent verdict activity in Philadelphia includes:

• McKivison v. Monsanto (Jan 2024): A jury awarded $2. 25 billion, the largest single-plaintiff verdict in the Philadelphia litigation. In June 2024, Judge Susan Schulman reduced this award to $400 million ($50 million compensatory, $350 million punitive). Bayer is appealing the liability verdict.
• Melissen v. Monsanto (Oct 2024): A jury awarded $78 million to the plaintiff, breaking a brief streak of defense wins.
• Caranci v. Monsanto: The Pennsylvania Superior Court affirmed a $175 million verdict in May 2025, rejecting Bayer’s preemption arguments prior to the Supreme Court’s intervention.
• Defense Wins: Bayer secured defense verdicts in Young (September 2024) and Womack (November 2024), demonstrating that liability is not guaranteed even in the plaintiff-friendly Philadelphia jurisdiction.

On March 4, 2026, Bayer received preliminary approval for a $7. 25 billion class action settlement designed to resolve future claims. This settlement method is explicitly linked to the outcome of the Durnell appeal; Bayer executives have described the settlement and the Supreme Court case as “mutually reinforcing” strategies to cap liability and end the litigation.

The Fracture: Anatomy of the Circuit Split

The route to the Supreme Court was paved by a fundamental rupture in federal appellate interpretation of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). For years, Bayer AG navigated a legal minefield where federal approval of Roundup’s label offered no shield against state-level failure-to-warn claims. This changed on August 15, 2024, when the Third Circuit Court of Appeals issued a ruling in Schaffner v. Monsanto that directly contradicted the Ninth and Eleventh Circuits, creating the “true conflict” necessary for certiorari. Understanding this split requires a granular examination of the opposing legal mechanics: the “Parallel Requirements” doctrine of the Ninth and Eleventh Circuits versus the “Regulatory Specificity” doctrine of the Third Circuit.

The Anti-Preemption Bloc: Hardeman and Carson

Until late 2024, plaintiffs successfully argued that EPA registration was a procedural step that did not absolve manufacturers of liability. This argument was cemented by two key appellate decisions that Bayer is challenging.

The Ninth Circuit: Hardeman v. Monsanto (2021)
In Hardeman, the Ninth Circuit affirmed a $25 million verdict against Monsanto, rejecting the company’s argument that FIFRA preempted California’s Proposition 65 warning requirements. The court relied heavily on the Supreme Court’s 2005 decision in Bates v. Dow Agrosciences, applying a “parallel requirements” test. The panel reasoned that FIFRA’s statutory text prohibits “misbranding,” defined broadly as labeling that contains statements that are “false or misleading.”

The Ninth Circuit held that because California common law requires a manufacturer to warn of known risks, it enforces FIFRA’s own prohibition against misbranding. Crucially, the court ruled that the EPA’s approval of a label without a cancer warning was not a “requirement” with the force of law that could override state tort duties. They pointed to FIFRA Section 136a(f)(2), which states that registration is only prima facie evidence of compliance, not a definitive defense. Under this logic, a jury could retroactively decide a product was misbranded, even if the EPA had explicitly approved it.

The Eleventh Circuit: Carson v. Monsanto (2024)
The Eleventh Circuit deepened this wound in February 2024 with its ruling in Carson v. Monsanto. The court focused on the “force of law” doctrine derived from United States v. Mead Corp. The panel concluded that the EPA’s registration process absence the requisite formality to preempt state law. It characterized the EPA’s label review as an administrative function rather than a legislative one, finding that the agency’s internal determination that glyphosate is non-carcinogenic did not carry the weight of a federal regulation. Consequently, Georgia’s failure-to-warn claims were deemed “parallel” to FIFRA’s misbranding provisions, leaving Bayer exposed to liability even with full federal compliance.

The Schaffner Pivot: The Third Circuit Breaks Rank

The legal shifted violently on August 15, 2024. In Schaffner v. Monsanto, the Third Circuit Court of Appeals unanimously held that FIFRA does preempt Pennsylvania state-law failure-to-warn claims, explicitly rejecting the reasoning of its sister circuits.

The Schaffner court dismantled the “parallel requirements” theory by focusing on the “Preapproval Regulation” (40 C. F. R. § 156). Unlike the Ninth and Eleventh Circuits, which looked at the broad statutory definition of misbranding, the Third Circuit zeroed in on the specific regulatory command: manufacturers cannot modify an EPA-approved label without agency permission. The court ruled that because the EPA had reviewed and approved Roundup’s label without a cancer warning, and because federal regulations prohibit adding warnings without approval, a state law compelling such a warning imposes a requirement ” to or different from” federal law.

This ruling established that the EPA’s label approval is not just a suggestion a federal mandate. The court noted that forcing a manufacturer to add a warning the EPA has rejected would compel them to violate federal labeling regulations, creating an impossibility preemption scenario.

Comparative Analysis of the Circuit Split

The between these courts is not academic; it represents two fundamentally different views of federal administrative power. The table outlines the mechanical differences in these rulings.

“The Third Circuit’s decision in Schaffner does not just disagree with Hardeman and Carson; it accuses them of ignoring the specific regulatory text in favor of broad statutory generalizations. This is the ‘true conflict’ the Supreme Court looks for.” , Legal Analysis of Docket 24-1068

The Schaffner ruling provided the “clean” vehicle for Supreme Court review. By isolating the “Preapproval Regulation” as the preemptive force, the Third Circuit created a binary choice for the Justices: either the EPA’s specific label approval carries the force of law, or the broad statutory prohibition on misbranding leaves the door open for fifty different state labeling regimes. This binary is the central question before the Court in the Durnell appeal.

Philadelphia Court of Common Pleas: The McKivison $2. 25 Billion Verdict

On January 26, 2024, the Philadelphia Court of Common Pleas delivered a financial shockwave to Bayer AG when a jury awarded $2. 25 billion to plaintiff John McKivison in *McKivison v. Monsanto*. This verdict, the largest single-plaintiff award in the history of the Roundup litigation at that time, fundamentally destabilized Bayer’s containment strategy and cemented Philadelphia’s reputation among corporate defendants as a “Judicial Hellhole.”

Verdict Anatomy and Damages Breakdown

The jury, deliberating for less than five hours, found that Monsanto’s glyphosate-based herbicide was a substantial factor in causing McKivison’s non-Hodgkin’s lymphoma. McKivison, a 49-year-old former landscaper from Lycoming County, Pennsylvania, testified to using Roundup for twenty years at his home and workplace. The financial penalty was structured to punish. The jury awarded $250 million in compensatory damages and a $2 billion in punitive damages. This 8: 1 ratio of punitive to compensatory damages signaled the jury’s intent to condemn what they viewed as decades of corporate malfeasance.

Trial and Procedural Controversies

The trial, presided over by Judge Susan Schulman, was marked by significant procedural friction that Bayer later in its appeals. A serious inflection point occurred when Judge Schulman struck approximately 45 minutes of testimony from a key defense witness. The witness, a Monsanto toxicologist, was as a fact witness began offering expert opinions on the safety of glyphosate. The court ruled this crossed the evidentiary line, instructing the jury to disregard the testimony, a move defense attorneys argued irreparably prejudiced the jury. Plaintiff attorneys Thomas Kline and Jason Itkin successfully argued that Monsanto had “ghostwritten” scientific studies and manipulated regulatory agencies to suppress evidence of glyphosate’s carcinogenicity. They presented internal company documents suggesting that Monsanto prioritized sales over safety, a narrative that resonated with the Philadelphia jury.

Judicial Reduction and Appellate Status

In June 2024, Judge Schulman granted Bayer’s post-trial motion for remittitur, slashing the total award to $400 million. While the reduction was substantial, erasing $1. 85 billion from the ledger, the remaining liability of $400 million for a single plaintiff remained financially untenable for Bayer’s settlement models. As of early 2026, the case remains locked in the appellate process before the Superior Court of Pennsylvania. Bayer maintains that the trial was “marred by significant and reversible errors,” specifically targeting the exclusion of evidence regarding the EPA’s consistent approval of glyphosate. The company that the $400 million judgment remains unconstitutionally excessive and ignores the *State Farm v. Campbell* guidance on due process limits for punitive damages.

Impact on Corporate Liability Provisions

The McKivison verdict, combined with the subsequent $78 million *Melissen* verdict in October 2024, forced Bayer to re-evaluate its litigation reserves. In August 2025, following these adverse outcomes and a separate loss in Missouri, Bayer allocated an additional $1. 37 billion to its litigation provisions. This capital injection was a direct response to the failure of the “containment” strategy in venues like Philadelphia, where juries continued to reject the federal preemption arguments that had found success in the Third Circuit’s *Schaffner* ruling. The persistence of these high-value verdicts in state courts demonstrates the bifurcation of Bayer’s legal reality: while federal appellate courts began to lean toward preemption in late 2024 and 2025, state courts in Pennsylvania and Missouri continued to generate nine-figure liabilities, keeping the company’s stock price depressed and its dividend policy under strict review.

Judicial Remittitur Data: McKivison Award Reduction to $400 Million

On June 4, 2024, the Philadelphia Court of Common Pleas executed a significant judicial intervention in the McKivison v. Monsanto litigation, slashing the original $2. 25 billion jury verdict by over 82%. Judge Susan I. Schulman issued the remittitur order, finding the jury’s initial award “unconstitutionally excessive” and unsupported by the evidentiary record regarding the plaintiff’s non-Hodgkin lymphoma diagnosis. This ruling represents a serious data point in the stabilization of Philadelphia’s mass tort verdicts, which had previously been flagged by legal analysts as a “judicial hellhole” due to outlier awards.

Verdict Reduction Mechanics

The remittitur did not cap punitive damages; it fundamentally recalculated the compensatory baseline. Judge Schulman determined that the jury’s award of $250 million for compensatory damages, intended to cover John McKivison’s pain, suffering, and economic losses, was disproportionate to the actual harm proven at trial. Consequently, the court reduced the compensatory component to $50 million. This reduction in the “actual harm” denominator necessitated a corresponding drop in punitive damages to maintain a constitutionally permissible ratio under the Due Process Clause.

Constitutional Ratios and Legal Rationale

The reduction aligns with federal jurisprudence established in State Farm Mutual Automobile Insurance Co. v. Campbell, which generally cautions against punitive-to-compensatory ratios exceeding single digits. While the original verdict presented an 8: 1 ratio ($2 billion to $250 million), the absolute size of the compensatory award was the primary legal vulnerability. By reducing the compensatory damages to $50 million, Judge Schulman set the punitive damages at $350 million, resulting in a 7: 1 ratio. This adjustment preserves the punitive intent of the jury, punishing Bayer for alleged failure to warn, while bringing the total financial penalty within the outer bounds of Pennsylvania and federal constitutional limits.

Litigation Posture and Appeal Status

even with the $1. 85 billion reduction, Bayer AG rejected the remittitur as a resolution. On June 5, 2024, the company issued a statement confirming it would appeal to the Superior Court of Pennsylvania. Bayer’s legal team that the liability verdict itself is flawed due to “significant and reversible errors” during the trial, including the admission of what they characterize as inflammatory testimony regarding corporate conduct. The company maintains that federal FIFRA regulations should preempt state-level failure-to-warn claims, a core legal argument currently fracturing federal circuit courts.

Conversely, the plaintiff’s legal team, led by Kline & Specter, signaled their intent to cross-appeal the reduction, seeking to reinstate the original $2. 25 billion verdict. They the jury’s decision reflected the of Monsanto’s conduct and the severity of McKivison’s cancer. This dual-appeal trajectory ensures that the McKivison case remain a bellwether for Pennsylvania state law interpretation of punitive damages in toxic torts well into 2026.

“While the court’s decision reduces the unconstitutionally excessive damage award, we still disagree with the ruling on the liability verdict… The trial was marred by significant and reversible errors that misled and inflamed the jury.” , Bayer AG Official Statement (June 5, 2024)

Impact on Philadelphia Mass Tort Program

The McKivison remittitur serves as a stabilizing method for the Philadelphia Court of Common Pleas, which had seen a surge in high-value verdicts in late 2023 and early 2024. By enforcing a $400 million cap on what was a multi-billion dollar outlier, the court signaled that while it remains a favorable venue for plaintiffs, there are functional ceilings to jury awards. This decision complicates the settlement calculus for plaintiff firms, who can no longer assume that billion-dollar headline verdicts survive post-trial motions intact.

SECTION 6 of 22: The Melissen Case: $78 Million Plaintiff Victory Breakdown

On October 10, 2024, the Philadelphia Court of Common Pleas delivered a significant blow to Bayer AG in *Melissen v. Monsanto Co.*, ending a brief defense winning streak and the volatility of the Philadelphia jurisdiction. The jury awarded plaintiff William Melissen and his wife Margaret a total of **$78 million**, a verdict that explicitly rejected Bayer’s arguments regarding federal preemption and scientific consensus.

Verdict Financial Deconstruction

The $78 million award was structured with a heavy emphasis on punitive measures, signaling the jury’s intent to penalize Monsanto for perceived corporate negligence rather than compensating the plaintiff for economic loss.

The 25: 1 ratio between punitive and compensatory damages immediately triggered legal scrutiny. The United States Supreme Court has historically indicated in cases like *State Farm v. Campbell* that punitive damage ratios exceeding single digits (9: 1) frequently violate due process. Bayer this in its immediate post-trial statements, labeling the award “unconstitutionally excessive.”

Trial Mechanics and The *Schaffner* Rejection

The *Melissen* trial was the sixth Roundup case heard in the Philadelphia Court of Common Pleas, a venue Bayer has frequently criticized as a “judicial hellhole.” Crucially, this trial proceeded *after* the Third Circuit Court of Appeals issued its ruling in *Schaffner v. Monsanto* on August 15, 2024. even with the *Schaffner* precedent, which held that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state law failure-to-warn claims, the presiding state court judge, Judge Craig Levin, denied Monsanto’s motions to dismiss the case or apply the federal preemption standard. This refusal demonstrated a serious jurisdictional firewall: Pennsylvania state courts in Philadelphia did not immediately align with the federal Third Circuit’s interpretation, allowing the *Melissen* jury to consider state-based negligence claims that *Schaffner* barred in federal court.

Plaintiff Profile and Allegations

William Melissen, a 51-year-old resident of Abington Township, Pennsylvania, was diagnosed with Non-Hodgkin’s Lymphoma in 2020. His legal team, led by Tom Kline of Kline & Specter and Jason Itkin of Arnold & Itkin, presented evidence that Melissen had used Roundup products consistently at his home and workplace from 1992 until his diagnosis. The plaintiff’s case hinged on two core arguments:

1. Causation: Melissen’s attorneys argued that glyphosate and other surfactants in Roundup were the direct proximate cause of his cancer, countering Bayer’s defense that Melissen’s illness was idiopathic or caused by other factors.
2. Failure to Warn: The jury found that Monsanto knew of the carcinogenic risks associated with its products failed to warn consumers, acting with “reckless indifference.”

Strategic for Bayer

The *Melissen* verdict disrupted Bayer’s narrative of stabilizing litigation. Just weeks prior, in September 2024, Bayer had secured a defense verdict in the *Young* case in the same courthouse. The *Melissen* outcome re-established the high-risk nature of the Philadelphia docket.

“We disagree with the jury’s verdict, as it conflicts with the overwhelming weight of scientific evidence… We believe that we have strong arguments on appeal to get this verdict overturned and the excessive damages eliminated or reduced.”
, Bayer AG Official Statement, October 11, 2024

This verdict serves as a primary exhibit in Bayer’s current petition to the US Supreme Court. It illustrates the “intolerable confusion” Bayer claims exists between state and federal courts. While the federal Third Circuit says these claims are illegal under FIFRA (*Schaffner*), the state Court of Common Pleas continues to award eight-figure sums for those exact claims (*Melissen*). This direct conflict creates the “split” mechanics required for Supreme Court intervention.

Defense Verdict Metrics: Young and Womack Trial Outcomes

While the *McKivison* and *Melissen* verdicts generated headlines for their financial liabilities, a parallel narrative emerged within the Philadelphia Court of Common Pleas (PCCP) throughout 2024. Bayer AG secured serious defense victories in *Young v. Monsanto* and *Womack v. Monsanto*, demonstrating that the Philadelphia jurisdiction, frequently characterized as a “judicial hellhole” by tort reform advocates, remains a battleground where plaintiff victories are not guaranteed. These verdicts provide essential data points for Bayer’s legal defense strategy, validating a causation-focused method even in the absence of federal preemption protections.

The *Young* Verdict: Breaking the Plaintiff Momentum

On September 13, 2024, a Philadelphia jury returned a defense verdict in *Young v. Monsanto*, halting a series of high-profile plaintiff wins. The trial, presided over by Judge Angelo Foglietta, centered on the claims of Ryan Young, a plaintiff who alleged that his non-Hodgkin lymphoma (NHL) was caused by exposure to Roundup. Unlike the *McKivison* trial, where the jury found egregious corporate misconduct warranting billions in punitive damages, the *Young* jury focused narrowly on specific causation. The defense successfully argued that the plaintiff’s medical history and the scientific consensus on glyphosate did not support a causal link to his cancer.

The *Young* verdict was particularly significant because it occurred shortly after the Third Circuit’s *Schaffner* ruling. Although the state court did not apply *Schaffner*’s preemption standard to dismiss the failure-to-warn claims, the defense victory on the merits suggested that Bayer could still win over urban juries by attacking the scientific validity of the plaintiff’s specific exposure claims.

The *Womack* Verdict: Reinforcing the Defense Wall

Two months later, on November 15, 2024, Bayer secured its third Philadelphia defense victory in *Womack v. Monsanto*. The trial, held before Judge Michael Erdos, involved plaintiff Judith Womack, who used Roundup for residential gardening between 2015 and 2019 before her cancer diagnosis. The jury voted 11-1 in favor of Monsanto, a decisive margin that underscored the effectiveness of the defense’s “alternative causation” strategy. In *Womack*, defense counsel highlighted the short duration of use (four years) compared to other plaintiffs who claimed decades of exposure, and presented expert testimony linking the plaintiff’s NHL to other risk factors unrelated to herbicides.

“The jury’s verdict… validates the Company’s strategy of taking cases to trial based on strong scientific and regulatory evidence. The verdict makes clear that the plaintiff failed to prove that Roundup was the cause of the injuries alleged.”
, Bayer AG Official Statement following the Womack verdict, November 2024.

Strategic of the 2024 Defense Wins

The *Young* and *Womack* verdicts, combined with the earlier *Kline* victory in March 2024, established a counter-narrative to the mass tort consolidation in Philadelphia. These outcomes reveal three serious metrics for investors and legal analysts:

1. Juror Discernment on Causation
even with the “judicial hellhole” reputation, Philadelphia juries have shown a capacity to distinguish between general corporate conduct and specific medical causation. In cases where the plaintiff’s exposure history is limited or alternative health factors are prominent (as in *Womack*), the defense has successfully decoupled the plaintiff’s injury from the product’s liability.

2. The Limits of the “Monsanto Papers”
Plaintiff attorneys frequently rely on internal Monsanto documents, the so-called “Monsanto Papers”, to incite juror anger regarding corporate transparency. The defense verdicts in *Young* and *Womack* indicate that while these documents are in driving up punitive damages (as seen in *McKivison*), they are insufficient to carry a verdict if the underlying scientific causation is weak.

3. Settlement use
These victories provide Bayer with essential use in settlement negotiations. By demonstrating that they can win 60% of the trials in a hostile jurisdiction (3 wins out of 5 trials in 2024), Bayer reduces the aggregate value of the remaining inventory of cases. The ability to secure defense verdicts forces plaintiff leadership to reconsider the risk profile of taking marginal cases to trial.

The oscillation between billion-dollar losses and complete defense exonerations in the same courthouse within the same year highlights the extreme volatility of the Roundup litigation. For Bayer, the *Young* and *Womack* verdicts are not just legal wins; they are statistical necessities required to prevent the collapse of their settlement containment strategy.

The Strategic Pivot: Anatomy of the $7. 25 Billion Framework

Bayer AG formally unveiled a $7. 25 billion settlement framework in February 2026 designed to cap the financial from the Roundup litigation. This proposal marks a definitive shift from the company’s previous “defend-at-all-costs” strategy. The framework attempts to resolve both current pending claims and future liabilities through a structured twenty-one-year payment schedule. This method relies on a “declining capped annual payment” model. It aims to provide the company with predictable cash flow outflows rather than the erratic spikes caused by jury verdicts like McKivison and Melissen.

The proposal allocates funds specifically for plaintiffs diagnosing Non-Hodgkin Lymphoma (NHL) over the two decades. The structure offers payouts ranging from $10, 000 to $165, 000 per claimant depending on the severity of the diagnosis and proof of exposure. These figures stand in clear contrast to the multi-million dollar awards granted by Philadelphia juries in 2024 and 2025. The plan requires approval from the Circuit Court of the City of St. Louis. It also operates independently of the Supreme Court’s review of the Durnell case. Bayer executives positioned this dual-track method as a necessary measure to “significantly contain” the litigation risks that have suppressed the company’s stock value for eight years.

2025 Financial Precursors and Provision Data

The financial architecture for this settlement was constructed throughout the fiscal year 2025. Bayer aggressively increased its litigation reserves in the quarters leading up to the announcement. On August 1, 2025, the company added $1. 37 billion (€1. 2 billion) to its provisions. By September 30, 2025, the total litigation provisions and liabilities had swelled from €7. 8 billion to €11. 8 billion. This 51 percent increase in reserves signaled to institutional investors that a major settlement vehicle was being assembled.

“The resolutions, including litigation costs, entail an increase in provisions and liabilities for litigation from 7. 8 billion euros as of Sept. 30 last year to 11. 8 billion euros.” , Bayer AG Financial Statement, Q3 2025.

The cost of these provisions weighed heavily on Bayer’s 2025 performance. The company reported a net loss of €3. 62 billion for the fiscal year 2025. This widened from a €2. 55 billion loss in 2024. Special items charges totaled €7. 96 billion in 2025. The vast majority of these charges were directly attributable to the Roundup litigation defense and settlement preparations. The company also maintained its dividend at the legal minimum of €0. 11 per share. This policy was implemented in 2024 to preserve cash for these exact liability payments.

Claim Volume and Resolution Metrics

The settlement framework addresses a specific volume of unresolved cases. As of October 15, 2025, Bayer reported a total of approximately 197, 000 registered Roundup claims since the litigation began. Of these, roughly 132, 000 had been resolved or deemed ineligible. This left a serious mass of approximately 61, 000 active cases. The $7. 25 billion proposal this remaining block and establishes the fund for future claimants who have not yet filed.

The between the settlement offer and trial outcomes remains a point of contention. The proposed average payout of $10, 000 to $165, 000 represents a fraction of the $400 million remitted judgment in McKivison. Plaintiff attorneys this “discount” is unjustified given the recent string of jury victories. Yet Bayer use the sheer volume of cases and the delay of appellate relief to force a standardized resolution. The company secured an $8 billion bank loan to finance the immediate tranches of the settlement. This liquidity move ensures that the payout method does not require an authorized capital increase that would further dilute shareholder value.

Market Reaction and Valuation Impact

Investor reaction to the mounting provisions in late 2025 was tepid. Bayer shares traded in the €36 to €37 range in early 2026. This valuation reflects a persistent “litigation discount.” The market had already priced in the need of a settlement exceeding $5 billion. Analysts at JP Morgan and Barclays noted in late 2025 that while the provisions were painful, they were necessary to remove the “existential threat” of uncapped liability. The 2026 outlook projects flat EBITDA of €9. 6 billion to €10. 1 billion. This stagnation indicates that the company’s operational recovery is still being suffocated by the legacy Monsanto liabilities.

Liability Provision Solvency: €11. 8 Billion Reserve Balance Sheet

As of March 5, 2026, Bayer AG’s balance sheet reflects a seismic recalibration of its legal defense strategy, with the total provision for litigation liabilities swelling to €11. 8 billion ($13. 9 billion). This figure, disclosed alongside the company’s delayed 2025 annual report, represents a dramatic increase from the €7. 8 billion reported just six months prior in September 2025. The surge is not an accounting adjustment; it is a direct financial scar left by the Philadelphia Court of Common Pleas verdicts and the subsequent need of a global containment strategy.

The Glyphosate Provision Spike

The core of this financial restructuring is the glyphosate-specific reserve, which stands at €9. 6 billion. This allocation was forced upward by a series of adverse jury awards in 2024 and 2025 that shattered the company’s previous containment models. Specifically, the McKivison and Melissen verdicts in Philadelphia demonstrated that even with the Schaffner preemption ruling, state court juries remained to award punitive damages in the hundreds of millions. Consequently, Bayer abandoned its piecemeal settlement method in favor of a detailed $7. 25 billion class settlement method proposed on February 17, 2026.

Cash Flow and Debt Re-Leveraging

The solvency of this reserve increase are immediate and severe. CEO Bill Anderson confirmed that the company expects negative free cash flow ranging between €1. 5 billion and €2. 5 billion for the fiscal year 2026. This deficit is driven by an anticipated €5 billion in cash payouts scheduled for the current year, primarily to fund the initial tranches of the $7. 25 billion settlement and resolve remaining legacy cases.

This cash drain reverses years of deleveraging progress. Net financial debt, which had dipped €30 billion at the end of 2025, is projected to rebound to the €32-33 billion range. The company has secured an $8 billion bank loan facility to this liquidity gap, ensuring that immediate settlement obligations do not trigger a solvency emergency, mortgaging near-term profitability to purchase legal certainty.

The Philadelphia “Tax” on Reserves

The trajectory of these reserves can be traced directly to the Philadelphia Court of Common Pleas. In Q2 2025, following the reduction of the McKivison award to $404 million and the persistence of high-value claims, Bayer recognized a €1. 7 billion provision “top-up.” This was followed by another €1. 064 billion in special charges in Q3 2025, as the Melissen verdict ($78 million) confirmed that plaintiff victories were not anomalies. These financial injections were tacit admissions that the “defend-and-appeal” strategy was too capital-intensive to sustain against a docket of 50, 000+ pending cases.

“The increase in provisions reflects a strategic pivot from managing litigation to ending it. The balance sheet accounts for a 21-year payment tail, ring-fencing the glyphosate liability at the cost of 2026 liquidity.”
, Bayer Financial Statement Note, March 4, 2026

Solvency vs. Strategy

While the €11. 8 billion figure is, it serves a dual purpose., it provides the financial bedrock for the settlement agreement currently awaiting preliminary approval in the St. Louis Circuit Court. Second, it acts as a balance sheet hedge against the Supreme Court’s decision in Monsanto v. Durnell. Should the Court rule in favor of preemption, of these reserves could theoretically be released back into equity. yet, if the Court denies relief, the funds are already encumbered, preventing a sudden liquidity shock. The market has priced in this “maximum pain” scenario, viewing the reserve as the ceiling of Bayer’s exposure rather than a variable estimate.

2026 Fiscal Guidance: EBITDA Stagnation and Cash Flow Deficits

As Bayer AG entered the quarter of 2026, the financial reality of its litigation exposure collided with its operational turnaround, resulting in a fiscal guidance that projected stagnation in earnings and a severe deficit in free cash flow. The company’s fiscal outlook, solidified by year-end 2025 data, revealed that the ” Shared Ownership” (DSO) restructuring savings were being systematically consumed by legal liabilities rather than fueling reinvestment or debt reduction.

EBITDA Stagnation and Margin Compression

The 2026 fiscal guidance pegged Group EBITDA before special items in the range of €9. 6 billion to €10. 1 billion on a currency-adjusted basis. While nominally stable compared to the 2025 baseline, this figure represented a significant stagnation in real terms, particularly when adjusted for inflation and the divestment of non-core assets. The projected EBITDA margin remained compressed between 20% and 22%, well the historical 30% benchmark that Bayer consistently achieved prior to the Monsanto acquisition.

Two primary factors drove this earnings paralysis:

• Pharmaceutical Patent Cliffs: The loss of exclusivity for the blockbuster anticoagulant Xarelto (rivaroxaban) in key European and Canadian markets accelerated, creating a revenue hole that new launches like Nubeqa and Kerendia could not fully plug in the immediate term.
• Crop Science Headwinds: Pricing power in the Crop Science division weakened as generic glyphosate competitors flooded the market, forcing Bayer to reduce premiums to maintain market share. The division’s EBITDA contribution was forecasted to remain flat, even with a 1-4% projected increase in core sales volume.

The Cash Flow emergency: Litigation vs. Liquidity

The most worrying metric in the 2026 guidance was the projection for Free Cash Flow (FCF). For the time in its modern history as a combined entity, Bayer guided toward a negative free cash flow of €1. 5 billion to €2. 5 billion. This deficit was not driven by operational failure, by the sheer velocity of settlement payouts mandated by the Philadelphia and federal dockets.

By December 31, 2025, Bayer had provisioned approximately €5. 0 billion specifically for litigation payouts to be executed in 2026. This cash outflow directly offset the €2 billion in operational savings generated by CEO Bill Anderson’s aggressive restructuring. The result was a “cash burn” scenario where every euro saved by terminating middle management was immediately redirected to plaintiff attorneys and settlement funds.

Debt Re-Leveraging and Credit Rating Pressure

The negative cash flow projection forced Bayer to reverse its deleveraging trajectory. After successfully reducing net financial debt to under €30 billion by the end of 2025, the 2026 guidance indicated a re-leveraging event, with debt expected to climb back to the €32 billion to €33 billion range. This increase was necessitated by the need to finance settlement payments through external borrowing rather than operating cash.

Credit rating agencies reacted with immediate skepticism. S&P Global Ratings and Moody’s maintained a negative outlook on Bayer’s credit profile entering 2026. The agencies the “litigation overhang” as a structural impediment to achieving the “A” category rating Bayer targeted. The cost of servicing this debt also rose, as Bayer was forced to problem bonds with higher coupon rates to attract investors wary of the company’s legal liabilities.

The “Legal Minimum” Dividend Policy

To preserve liquidity amidst these deficits, Bayer confirmed the continuation of its draconian dividend policy. The Board of Management proposed a dividend of €0. 11 per share for the 2025 fiscal year (paid in 2026), the legal minimum required under German stock corporation law. This marked the third consecutive year of minimum payouts, removing Bayer from the portfolios of income-focused institutional investors.

“The decision to pay the legal minimum dividend is not a reflection of our operational health, a mathematical need imposed by our legal obligations. We are prioritizing the survival of the balance sheet over shareholder returns in the short term.”
, Excerpt from Bayer AG Investor Relations Statement, December 2025.

DSO Implementation: Savings Without Solvency

CEO Bill Anderson’s ” Shared Ownership” model achieved its operational by late 2025, eliminating over 5, 000 management roles and reducing bureaucracy costs by the targeted €2 billion. yet, the 2026 guidance laid bare the futility of these measures in the face of the litigation tsunami. The efficiency gains did not translate into net income growth or debt reduction; they subsidized the legal defense and settlement apparatus.

The disconnect between operational efficiency and financial solvency created a precarious for 2026. While the core businesses of Crop Science and Pharmaceuticals remained profitable on an operating basis, the corporate entity was functionally bleeding cash. This “zombie” status, where a healthy operation supports a distressed balance sheet, fueled renewed calls from activist investors for a breakup of the conglomerate, a strategy Anderson had resisted throughout 2025.

Dividend Policy Adjustments: Shareholder Payout Cuts for Liquidity

The financial from the Philadelphia verdicts and the protracted federal litigation has forced Bayer AG into a defensive capital allocation strategy, characterized by a draconian reduction in shareholder returns. To preserve liquidity for legal settlements and debt servicing, the company executed a historic pivot in February 2024, slashing its dividend to the legal minimum required under German law. This “containment strategy,” as described by CEO Bill Anderson, prioritizes the accumulation of a litigation war chest over immediate investor yield, a posture that has extended well into the 2026 fiscal.

The 95% Reduction: A Strategic Pivot

In February 2024, Bayer AG announced it would reduce its dividend for the 2023 fiscal year to **€0. 11 per share**, a 95% decrease from the **€2. 40 per share** paid the previous year. This decision was not an austerity measure a structural shift designed to remain in place for three years (covering fiscal years 2023, 2024, and 2025). The mathematical impact of this cut is substantial. By lowering the payout to the statutory minimum, Bayer retains approximately **€2. 3 billion annually** in free cash flow. Over the three-year period, this aggregates to nearly **€7 billion** in preserved capital, funds explicitly earmarked to address the company’s net financial debt, which stood at approximately **€34. 5 billion** at the time of the initial announcement, and to service the escalating costs of the Roundup and PCB litigation.

2026 Liquidity Outlook and Settlement Funding

As of March 2026, the need of this austerity policy has been reinforced by new financial liabilities. On February 17, 2026, Bayer proposed a **$7. 25 billion nationwide class settlement** to resolve current and future Non-Hodgkin lymphoma (NHL) claims. This structured settlement involves capped annual payments over a 21-year period, designed to run parallel to the Supreme Court’s review of *Monsanto Co. v. Durnell*. The immediate financial toll of this settlement is severe. CFO Wolfgang Nickl confirmed that Bayer expects **negative free cash flow** for the full year 2026, driven by approximately **€5 billion** in projected litigation payouts. These payouts include the initial funding for the class settlement as well as resolutions for legacy PCB environmental cases. Consequently, the Board of Management has confirmed that the dividend for the 2025 fiscal year (payable in April 2026) remain at the floor of **€0. 11 per share**.

Dividend History and Financial Impact (2015, 2025)

The trajectory of Bayer’s dividend payments illustrates the direct correlation between the Monsanto acquisition (closed in 2018) and the subsequent of shareholder value due to legal liabilities.

Integration with the Supreme Court Strategy

The dividend policy is inextricably linked to the *Durnell* appeal. Management has framed the liquidity preservation as a to reach a “post-litigation” state. CEO Bill Anderson stated that the $7. 25 billion settlement and the Supreme Court case are “mutually reinforcing.” The logic holds that the dividend cuts provide the cash required to fund the settlement’s initial tranches without triggering a liquidity emergency or a credit rating downgrade, while the Supreme Court ruling is expected to cap future liability by enforcing federal preemption. yet, the persistence of the €0. 11 dividend through the 2026 payment pattern indicates that the financial pressure has not abated. Even with the *Durnell* certiorari grant, the immediate cash demands of the *McKivison* and *Melissen* verdicts, alongside the new settlement structure, require Bayer to operate with minimal shareholder distributions. The company has signaled that a return to pre-2023 dividend levels is contingent upon a significant reduction in net financial debt (target range €30-32 billion) and a definitive end to the litigation uncertainty, neither of which is guaranteed before 2027.

“This is a choice for speed and containment over a protracted legal battle. Our amended dividend policy… help us do so.”
, Bill Anderson, CEO, Bayer AG (February 2024/Reaffirmed Feb 2026)

The market reaction has been one of resigned acceptance. While the initial cut in 2024 caused a sharp sell-off, the continued adherence to the minimum payout in 2026 was largely priced in by institutional investors who view the liquidity preservation as essential for the company’s survival against the backdrop of multi-billion dollar legal exposures.

The December 2025 Pivot: Federal Re-

On December 1, 2025, the trajectory of the national Roundup litigation shifted when U. S. Solicitor General D. John Sauer filed an amicus curiae brief in Monsanto Co. v. Durnell (Docket No. 24-1068). The filing, submitted in response to the Supreme Court’s June 2025 invitation for the government’s views, urged the justices to grant certiorari and rule that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state-law failure-to-warn claims. This intervention marked a formal restoration of the federal government’s support for Bayer AG, reversing the position held by the Department of Justice since 2022.

The Solicitor General’s brief argued that the Environmental Protection Agency (EPA) exercises “detailed regulatory authority” over pesticide labeling. Sauer contended that because the EPA has consistently reviewed glyphosate, most in its 2020 Interim Registration Review, and determined it is “not likely to be carcinogenic to humans,” any state court verdict penalizing a manufacturer for omitting a cancer warning creates an irreconcilable conflict with federal law. The brief explicitly stated that the 2024 Third Circuit decision in Schaffner v. Monsanto correctly interpreted the law, while the Ninth and Eleventh Circuits had erred in earlier rulings.

The Prelogar Reversal and the 2022-2025 Gap

The 2025 filing stands in clear contrast to the government’s stance three years prior. On May 10, 2022, then-Solicitor General Elizabeth Prelogar advised the Supreme Court to deny certiorari in Monsanto Co. v. Hardeman. In that brief, the Biden administration argued that FIFRA did not prevent states from imposing additional warning requirements, provided those warnings did not directly contradict federal directives. Prelogar’s interpretation left Bayer exposed to billions in liability across state jurisdictions, a position that contributed to the Court’s denial of the Hardeman and Pilliod appeals in June 2022.

Bayer executives and legal analysts frequently the “Prelogar pivot” as a primary driver of the litigation’s persistence through 2023 and 2024. The December 2025 brief acknowledged this shift, noting that ” of the Third Circuit’s intervening decision in Schaffner and the change in administration,” the United States had reexamined its legal arguments. The document returned to the “impossibility preemption” theory advanced during the 2019-2020 period: that a private party cannot comply with both a state duty to warn of cancer and a federal prohibition against “false and misleading” labels.

EPA Regulatory Consistency Metrics (2015-2025)

The Solicitor General’s argument relies heavily on the stability of the EPA’s scientific findings regarding glyphosate. even with political changes in the executive branch, the agency’s career scientists have maintained a consistent classification for the chemical.

The “Force of Law” Argument

A central pillar of the Solicitor General’s 2025 intervention is the assertion that the EPA’s labeling decisions carry the force of law. The brief highlights that FIFRA mandates the EPA to determine whether a pesticide causes “unreasonable adverse effects on the environment.” Sauer argued that a jury verdict in Missouri or Pennsylvania nullifies this federal determination by treating the EPA-approved label as defective.

“When the expert federal agency has reviewed all available data and determined that a warning is scientifically unfounded and would be misleading, a state jury cannot impose liability for failing to provide that very warning. To hold otherwise is to permit 50 separate juries to act as ad hoc regulatory agencies.”
, Brief for the United States as Amicus Curiae, Monsanto Co. v. Durnell, Dec. 1, 2025.

This argument directly attacks the legal foundation of the McKivison and Melissen verdicts in Philadelphia. In those cases, state judges ruled that the EPA’s absence of a cancer warning did not absolve Bayer of liability under Pennsylvania state law. The Solicitor General’s brief contends that these rulings violate the Supremacy Clause of the Constitution.

Impact on the Certiorari Grant

The Supreme Court’s decision to grant certiorari in Durnell on January 16, 2026, followed the Solicitor General’s recommendation by exactly 46 days. Historical that the Court grants review in approximately 80% of cases where the Solicitor General recommends doing so. The intervention provided the “federal interest” signal required to elevate the case from a private tort dispute to a matter of national regulatory importance.

The brief also addressed the circuit split, noting that the between the Third Circuit’s Schaffner ruling and the Ninth Circuit’s Hardeman precedent created an untenable situation for national commerce. Manufacturers faced a legal paradox: a label compliant in New Jersey (Third Circuit) could trigger liability in California (Ninth Circuit). The Solicitor General urged the Court to resolve this “intolerable conflict” to ensure uniform enforcement of FIFRA.

Legislative Shield Status: Farm Bill Lobbying Expenditures

While Bayer AG pursues judicial immunity through the Supreme Court in *Monsanto Co. v. Durnell*, the conglomerate simultaneously executes a capital-intensive legislative strategy designed to render state failure-to-warn claims federally preempted. This “Plan B” relies on inserting specific liability shields into the massive, must-pass Farm Bill, overruling juries in Philadelphia and California by congressional fiat.

The $9. 19 Million Lobbying Blitz

Federal disclosure data reveals that Bayer escalated its influence operations significantly as the *McKivison* and *Melissen* verdicts destabilized its litigation defense. In 2025 alone, Bayer reported spending **$9. 19 million** on federal lobbying, a figure that show the urgency of its legislative push. This expenditure funded a network of at least 13 outside lobbying firms, including **Ballard Partners**, a firm led by Brian Ballard, a top fundraiser for the 2024 Trump campaign. The lobbying architecture extends beyond direct corporate spending. Trade associations such as **CropLife America**, the **American Chemistry Council**, and the **National Corn Growers Association**, all aligned with Bayer’s preemption goals, spent a combined **$22 million** in 2025. These groups operate as force multipliers, framing the liability shield not as corporate protectionism as a need for food security and regulatory uniformity.

The method: H. R. 4288 and the Farm Bill Rider

The legislative vehicle for this immunity is the **Agricultural Labeling Uniformity Act** (H. R. 4288), introduced in the 118th Congress by Representatives Dusty Johnson (R-SD) and Jim Costa (D-CA). The bill’s core provision mandates that the Environmental Protection Agency (EPA) holds exclusive authority over pesticide labeling, so prohibiting states from requiring warnings that differ from federal findings. As of March 3, 2026, this language has been folded into the House Agriculture Committee’s draft of the **Farm, Food, and National Security Act of 2026 (H. R. 7567)**. If enacted, Section 10204 of the draft bill would legally nullify claims like those brought by John McKivison, who successfully argued that Bayer failed to warn him of glyphosate’s carcinogenic risks even with EPA approval. The provision that a “patchwork” of state labels disrupts interstate commerce, a narrative Bayer has cultivated since the initial *Hardeman* verdict.

State-Level “Test Kitchens” and the “Cancer Gag Act”

Bayer did not wait for federal action to test these provisions. Throughout 2024 and 2025, the company deployed lobbyists to state legislatures to pass local versions of the preemption shield. * **Iowa:** In 2025, Bayer spent **$123, 250** on lobbying in Iowa, nearly double its average annual spend in the state, pushing Senate File 394. Opponents, including trial lawyer associations and environmental groups, branded the bill the “Cancer Gag Act.” * **Victories:** While the Iowa bill stalled, similar measures passed in **Georgia** and **North Dakota** in 2025, creating state-level statutory defenses that Bayer cites in ongoing litigation. * **Missouri:** In Bayer’s U. S. home state, repeated attempts to pass liability shields faced fierce bipartisan resistance remain a legislative priority for the 2026 session.

Political Fracture: The MAHA Complication

The 2026 legislative push faces a unique political complication within the Republican coalition. While Bayer’s lobbyists use ties to the Trump administration, the **”Make America Healthy Again” (MAHA)** movement, associated with Health and Human Services Secretary Robert F. Kennedy Jr., has identified FIFRA preemption as a target. This internal fracture creates a volatile environment for the Farm Bill. A coalition of over 160 lawmakers, including 135 Democrats and libertarian-leaning Republicans like Rep. Thomas Massie (R-KY), formally opposed the preemption rider in February 2026. They that the provision violates the Tenth Amendment by stripping states of their police powers to protect public health.

” not allow Big Ag corporations like Bayer to use their ill-begotten pesticide profits to boost private coffers at the expense of the sick.”
, *Jennifer Breon, Iowa Organizer, Food & Water Watch (August 2025)*

2019-2025 Lobbying Expenditure Analysis

The following table tracks the escalation in lobbying expenditures by Bayer and its primary trade proxy, CropLife America, during the serious litigation window.

Current Status: The March 2026 Markup

On March 3, 2026, the House Agriculture Committee marked up H. R. 7567, retaining the controversial preemption language even with the MAHA opposition. The inclusion of this rider guarantees a contentious floor fight. If the provision survives the House, it faces a formidable firewall in the Senate, where Democratic leadership has signaled that any retroactive liability shield for glyphosate is a “poison pill” that could sink the entire Farm Bill. Consequently, Bayer’s legislative shield remains a high- gamble, leaving the Supreme Court’s *Durnell* decision as the company’s most viable route to ending the litigation emergency.

SECTION 14 of 22: PCB Litigation Vectors: The Sky Valley $185 Million Reinstatement

On October 30, 2025, the Washington Supreme Court delivered a decisive financial and legal blow to Bayer AG by reinstating a $185 million jury verdict in *Erickson v. Monsanto Co.* This ruling, which reversed a 2024 state appellate decision, dismantled Bayer’s primary defense strategy in the Pacific Northwest: the reliance on Washington’s restrictive product liability statutes to cap damages. The decision not only solidified the liability for the three teacher plaintiffs in *Erickson* also reactivated a dormant liability pipeline involving eight other verdicts and nearly $1. 5 billion in chance exposure that Bayer had previously segregated from its settlement calculations.

The Erickson Verdict: Anatomy of the Reinstatement

The *Erickson* case, originally tried in 2021, served as the bellwether for the Sky Valley Education Center (SVEC) litigation cluster. The plaintiffs, Kerry Erickson, Michelle Leahy, and Joyce Marquardt, alleged that polychlorinated biphenyls (PCBs) leaking from fluorescent light ballasts at the Monroe, Washington school caused permanent neurological damage and widespread poisoning. The jury awarded them $185 million, a figure heavily weighted with punitive damages. In May 2024, the Washington Court of Appeals vacated this verdict. The appellate panel ruled that the trial court erred by applying Missouri law to the punitive damages claim. Under Washington’s Product Liability Act (WPLA), punitive damages are generally prohibited. By reverting to Washington law, the appellate court stripped the punitive component, reducing Bayer’s liability to compensatory damages only. The October 2025 Supreme Court ruling, yet, rejected the appellate court’s reasoning in a 6-3 decision. Chief Justice Debra Stephens, writing for the majority, established a new “choice of law” precedent for toxic torts involving out-of-state corporations. The Court held that because Monsanto ( Bayer) made the serious decisions regarding PCB manufacture, safety warnings, and marketing at its headquarters in St. Louis, Missouri law governed the punitive damages analysis. Missouri law permits punitive damages, whereas Washington law does not.

“When a party raises an actual conflict of substantive law, Washington courts apply the law of the state with the most significant relationship to that particular problem. Under this test, Missouri law applies to govern the problem of repose and punitive damages.” , *Washington Supreme Court Majority Opinion, October 30, 2025*

This legal pivot is significant. It prevents Bayer from using Washington’s stricter plaintiff protections as a shield for conduct that originated in a jurisdiction with more punitive liability standards.

Financial Impact: The Punitive Multiplier

The reinstatement of the $185 million award forces Bayer to re-evaluate its reserve adequacy for the remaining Sky Valley docket. The breakdown of the *Erickson* award illustrates the danger of the Missouri law application:

The punitive damages constitute approximately 92% of the total award. By validating the application of Missouri law, the Washington Supreme Court has authorized a 10x multiplier on compensatory damages for all pending Sky Valley appeals where similar fact patterns exist.

The Statute of Repose Failure

Beyond punitive damages, the *Erickson* ruling dismantled Bayer’s “statute of repose” defense. Washington law includes a 12-year statute of repose, which bars product liability claims filed more than 12 years after the product changed hands. Since the PCB-laden light ballasts were installed at Sky Valley decades prior to the 2018 lawsuits, Bayer argued the claims were time-barred. The Supreme Court majority ruled that the statute of repose is a substantive legal problem, not procedural. Therefore, the same “significant relationship” test applied. Since the decision to release the products into the stream of commerce occurred in Missouri, and the alleged concealment of data happened in Missouri, the Court applied Missouri’s statute of repose—which is less restrictive regarding the discovery of latent injuries. The dissent, led by Associate Chief Justice Charles Johnson, argued that this interpretation nullifies Washington’s legislative intent to protect manufacturers from indefinite liability. “Courts are not supposed to start their analysis with policy p

The McKivison Volatility Event: January 2024

The financial markets delivered an immediate and punitive verdict on Bayer AG following the Philadelphia Court of Common Pleas ruling in McKivison v. Monsanto. On January 29, 2024, the trading day after the jury awarded $2. 25 billion in damages, Bayer shares plummeted 5. 7% on the Frankfurt Stock Exchange, reaching an eight-week low. This single-day capitalization loss erased approximately €2 billion in shareholder value, reflecting the market’s acute sensitivity to “headline risk” rather than legal fundamentals. The sheer magnitude of the punitive damages, $2 billion of the total award, forced institutional investors to recalibrate their risk models, pricing in the possibility of a “nuclear verdict” contagion in the Philadelphia jurisdiction.

Market analysts reacted swiftly to the Philadelphia destabilization. Bank of America downgraded Bayer from “Neutral” to “Underperform” immediately following the verdict, citing the “overhang” created by the renewed litigation intensity. The volatility index for Bayer options spiked, indicating that traders were paying a premium for protection against further downside. This reaction underscored a serious disconnect: while Bayer’s legal team emphasized the high probability of remittitur (reduction of damages) on appeal, the equity markets priced the verdict at face value, penalizing the company for the reputational and cash-flow uncertainty introduced by the Philadelphia Court of Common Pleas.

The Dividend Capitulation: February 2024

The fiscal consequences of the litigation drag materialized less than a month later. In February 2024, Bayer announced a radical restructuring of its capital allocation policy, slashing its dividend by 95% to the legal minimum of €0. 11 per share. This decision, valid for three years, was explicitly linked to the need for debt reduction and litigation reserves. The market viewed this not as a prudent balance sheet maneuver, as a signal of distress. The dividend cut removed Bayer from income-focused portfolios and index funds that require yield thresholds, triggering a mechanical sell-off that further depressed the stock price.

“One of our top priorities is reducing debt and increasing flexibility. Our amended dividend policy… help us do so.”
, Bill Anderson, CEO of Bayer AG, February 2024

The correlation between the Philadelphia verdicts and the dividend policy was unmistakable to credit rating agencies. Following the dividend announcement and the continued litigation pressure, the cost of insuring Bayer’s debt against default (Credit Default Swaps) widened. Investors demanded higher yields to hold Bayer bonds, reflecting a risk premium directly attributable to the uncertainty emanating from U. S. courtrooms.

The Schaffner Rebound: August 2024

Investor sentiment underwent a sharp reversal in the third quarter of 2024, driven by the Third Circuit Court of Appeals ruling in Schaffner v. Monsanto. On August 15, 2024, the court held that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempted Pennsylvania’s state-law failure-to-warn claims. The market reaction was euphoric: Bayer shares surged nearly 11% in intraday trading on August 16, 2024, marking one of the largest single-day gains since the Monsanto acquisition.

Market Impact of Major Legal Events (2024-2025)

The “Schaffner Rally” demonstrated that the market was heavily discounting Bayer stock based on the assumption of endless litigation. The moment a viable route to the Supreme Court appeared, via the Circuit Split created by Schaffner, institutional capital flowed back into the stock. Analysts at Jefferies and Kepler Cheuvreux issued notes highlighting that the ruling fundamentally altered the risk profile, transforming the litigation from an open-ended liability to a binary outcome dependent on the Supreme Court.

Institutional Positioning and S&P Outlook: 2025

even with the legal victories in the Third Circuit, the broader financial metrics remained constrained by the litigation reserves. In September 2025, S&P Global Ratings revised its outlook on Bayer to “Negative” while affirming its BBB rating. The agency the “material decline” in adjusted EBITDA due to litigation provisions, which had ballooned by an additional €1. 7 billion in the second quarter of 2025 alone. S&P projected that Bayer’s adjusted debt-to-EBITDA ratio would deteriorate to between 4. 5x and 4. 7x in 2025, well above the target range for an investment-grade issuer.

This credit outlook dampened the equity recovery, creating a ceiling for the stock price throughout mid-2025. Institutional ownership data from this period showed a rotation: long-term “value” funds began to accumulate shares, betting on the Supreme Court outcome, while “growth” and “income” funds remained largely absent. The market treated Bayer as a distressed asset with a high-upside call option attached to the Durnell petition.

The Solicitor General Surge: December 2025

The final major market movement within the verified period occurred in early December 2025. When the U. S. Solicitor General filed a brief urging the Supreme Court to grant certiorari in the Durnell case, Bayer shares spiked 12. 1%. This move was significant because it signaled federal executive branch with Bayer’s preemption argument, historically a strong predictor of Supreme Court review.

Trading volumes on the Frankfurt exchange tripled the daily average, indicating high-conviction buying from hedge funds and arbitrage desks. The market pricing shifted from a “possibility” of review to a “probability,” ignoring the lingering risks from the Philadelphia Court of Common Pleas. By the close of 2025, Bayer’s market capitalization had recovered of the losses sustained after the McKivison verdict, although it remained deeply depressed compared to its pre-Monsanto acquisition levels. The price action confirmed that for investors, the only metric that mattered was the route to Washington, D. C.

Executive Restructuring: CEO Anderson’s Personnel Reduction

The ” Shared Ownership” Mandate

In a radical departure from Bayer AG’s traditional hierarchical structure, CEO Bill Anderson implemented the ” Shared Ownership” (DSO) operating model in January 2024. The initiative, designed to the conglomerate’s bureaucratic ossification, aimed to shift 95% of decision-making power from managers to “the people doing the work.” By March 2026, the execution of this model has fundamentally reshaped the company’s workforce, driven by the urgent need to free up liquidity for mounting litigation liabilities.

Anderson’s strategy targeted the elimination of “coordination” roles, middle management that he argued stifled innovation and slowed reaction times. The restructuring reduced organizational from twelve to six, a compression intended to save €2 billion annually by the end of 2026. This capital preservation strategy is not operational; it is a defensive fortification against the multi-billion dollar legal exposure arising from the Roundup and PCB dockets.

Workforce Contraction Metrics (2024, 2025)

The personnel reductions executed under the DSO framework have been severe and rapid. By December 31, 2025, Bayer had eliminated approximately 13, 500 positions globally. A distinct feature of this restructuring was its focus on the upper echelons of the workforce; unlike traditional austerity measures that target frontline labor, nearly 40% of the eliminated roles, approximately 5, 500 positions, were managerial.

The geographic distribution of these cuts reflects labor protections. In the United States, where employment is at-, the majority of the reductions were completed by late 2025. In Germany, strict labor laws and agreements with the Works Council have extended the timeline, with guaranteed employment protections expiring only at the end of 2026. Consequently, the full financial realization of the German workforce reduction not materialize on the balance sheet until the 2027 fiscal year.

Financial Impact and Litigation Liquidity

The primary driver for these aggressive cuts is the need to service Bayer’s debt and legal obligations without liquidating core assets. By the end of 2025, Bayer reported net financial debt of €29. 8 billion, a reduction achieved largely through these austerity measures and improved cash flow management. The €2 billion in annual savings targeted by the DSO model is serious; in 2026 alone, Bayer projects litigation-related payouts to reach approximately €5 billion.

“We kept the great majority of the talent that we need to drive our progress, we took out the gatekeepers that, frankly, in all large multinationals, they just slow everything down.” , Bill Anderson, CEO, Q3 2025 Earnings Call.

even with the headcount reductions, Bayer’s 2025 financial performance remained constrained. Group sales hovered around €45. 6 billion, with EBITDA margins under pressure from the very litigation costs the restructuring aims to offset. The stock price, which hit a 20-year low in November 2024, has shown only modest recovery, signaling that the market views the restructuring as a necessary survival tactic rather than a growth catalyst.

Management Compression Analysis

The structural flattening of Bayer is visually distinct when comparing the 2023 baseline to the 2026 operational state. The removal of six of management has forced a cultural shift toward “90-day sprints” and autonomous teams, a method borrowed from the tech sector untested at this in a regulated pharmaceutical environment.

This compression has not been without friction. Internal reports indicate that while decision speed has improved, the loss of institutional knowledge, particularly in the Crop Science division, has created operational bottlenecks in regulatory compliance, a serious area given the ongoing EPA scrutiny.

Executive Compensation Adjustments

Parallel to the workforce reductions, executive compensation has undergone significant recalibration. In 2024, CEO Bill Anderson’s total compensation dropped 21% to €8. 84 million, a signal to shareholders that leadership is sharing the load of the restructuring. yet, the executive team was simultaneously streamlined, with the departure of three Crop Science executives in early 2024 and the reduction of the Pharmaceutical leadership team from 14 to 8 members. This consolidation concentrates accountability also heightens the risk profile for the remaining leadership as they navigate the company through its most litigious period in history.

Scientific Causation Admissibility: State Court Daubert Rulings

The between federal and state court gatekeeping standards for scientific evidence has become the central mechanic driving Bayer’s liability exposure in 2026. While the Third Circuit’s Schaffner ruling erected a federal preemption shield based on EPA labeling, state courts in Pennsylvania and Missouri have systematically dismantled similar defenses by admitting plaintiff expert testimony linking glyphosate to Non-Hodgkin’s Lymphoma (NHL). These admissibility rulings, grounded in state-specific applications of Frye and Daubert standards, provided the evidentiary foundation for the multi-billion dollar verdicts that forced the Supreme Court’s intervention in Monsanto v. Durnell.

Pennsylvania’s Frye Standard: The Philadelphia Breach

The Philadelphia Court of Common Pleas (PCCP), operating under the Frye “general acceptance” standard, has emerged as the primary jurisdiction where plaintiff scientific theories survive defense challenges. Unlike the federal Daubert standard, which requires judges to assess the reliability of the methodology itself, Pennsylvania’s Frye test focuses on whether the methodology is generally accepted by the relevant scientific community. In the mass tort context, PCCP judges have consistently ruled that the International Agency for Research on Cancer (IARC) 2015 classification of glyphosate as a “probable human carcinogen” constitutes a generally accepted methodology for causation experts, neutralizing Bayer’s reliance on EPA consensus.

This judicial posture was solidified in the McKivison and Melissen trials. In McKivison (January 2024), Judge Susan Schulman admitted plaintiff experts who extrapolated causation from the IARC data, rejecting Bayer’s argument that such extrapolation was “junk science” inadmissible under federal standards. Conversely, the court strictly policed defense witnesses; Judge Schulman reprimanded a Monsanto toxicologist for offering expert opinions while only as a “fact witness,” a procedural error that undermined the defense’s ability to counter the plaintiff’s narrative.

The Pennsylvania Superior Court further entrenched this admissibility standard in 2025. On May 8, 2025, the appellate panel affirmed the $175 million verdict in Caranci v. Monsanto, ruling that the trial court properly admitted expert testimony linking Roundup to the plaintiff’s cancer. Less than two months later, on June 25, 2025, the same court upheld the $3. 5 million Martel verdict, explicitly rejecting Bayer’s contention that the expert opinions absence a sufficient scientific footprint. These appellate affirmations signaled to the PCCP that its permissive application of Frye regarding glyphosate toxicity was legally sound, clearing the route for the Melissen verdict in October 2024.

Missouri’s Daubert Application: The Durnell Paradox

While Pennsylvania utilized Frye, the Missouri courts applied a statutory version of the Daubert standard (Section 490. 065. 2 RSMo) in Durnell v. Monsanto, the case before the Supreme Court. even with Daubert’s theoretically stricter gatekeeping role, requiring judges to act as arbiters of scientific reliability, the Missouri Circuit Court for the City of St. Louis admitted plaintiff experts who testified that Roundup’s formulation possessed a synergistic toxicity greater than glyphosate alone. This ruling demonstrated that even under Daubert, state courts could reach conclusions diametrically opposed to federal counterparts like the Schaffner court.

The Missouri Court of Appeals, Eastern District, affirmed this admission in February 2025. The court held that the experts’ reliance on differential etiology and the IARC monograph satisfied the reliability prongs of Daubert, regardless of the EPA’s contrary regulatory stance. This ruling created a serious paradox: federal courts in the Third Circuit were excluding failure-to-warn claims based on federal preemption, while Missouri state courts, applying federal-style Daubert rules, were admitting the underlying scientific evidence that substantiated those very claims.

Comparative Admissibility Outcomes (2024-2025)

The following table contrasts key admissibility rulings in state courts against the federal baseline, highlighting the specific method used to admit plaintiff evidence.

The “Junk Science” Defense and Judicial Rejection

Bayer’s primary defense strategy in state courts has been to frame plaintiff expert testimony as “junk science” that contradicts the “worldwide regulatory consensus.” In the Melissen trial, defense counsel argued that admitting Dr. Durrani’s testimony on specific causation, linking the plaintiff’s hairy cell leukemia to Roundup, violated the court’s gatekeeping duty because no regulatory body (EPA, EFSA, Health Canada) had confirmed such a link. The PCCP rejected this argument, ruling that regulatory consensus is not the sole metric for scientific validity in a tort setting. The court found that the between the IARC’s hazard assessment and the EPA’s risk assessment created a triable problem of fact for the jury, rather than a barrier to admissibility.

This judicial philosophy in Pennsylvania and Missouri insulates state court verdicts from the scientific skepticism frequently found in federal venues. By treating the EPA’s findings as one piece of evidence rather than a dispositive scientific truth, state judges have allowed juries to weigh the credibility of the IARC monograph against Bayer’s internal studies. The result is a liability where the admissibility of scientific causation is all guaranteed in key jurisdictions, leaving the Supreme Court’s review of the Durnell preemption argument as Bayer’s last line of defense against the scientific evidence itself.

“The jury’s verdict was a condemnation of 50 years of misconduct… based on damning testimony about of the most egregious corporate misconduct in American history.”
, Thomas R. Kline, Lead Counsel for John McKivison, following the admission of plaintiff scientific evidence (January 26, 2024).

European Shareholder Litigation: The Cologne District Docket

Status of Proceedings: Investors v. Bayer

As of March 2026, the Cologne District Court (Landgericht Köln) continues to oversee the massive securities fraud litigation captioned Investors v. Bayer. The plaintiff class, represented by the Tübingen-based law firm TILP, seeks approximately €2. 2 billion in damages. The core allegation remains that Bayer management failed to disclose the true extent of the financial risks associated with the 2018 Monsanto acquisition, specifically regarding the glyphosate liability exposure.

The docket has not yet reached a final judgment. yet, the procedural posture shifted in late 2025 following the admission of new evidence from U. S. proceedings. The court is currently examining whether the “Monsanto Papers”, internal documents revealing company scientists’ involvement in ghostwriting safety studies, demonstrate that Bayer’s due diligence was grossly negligent. A ruling on the preliminary questions of liability (Musterverfahren) is expected later in 2026, which determine if the class can proceed to individual damage assessments.

The Philadelphia Verdicts: A Liability Catalyst

The trajectory of the German shareholder suits has been directly altered by a series of adverse jury verdicts in the Philadelphia Court of Common Pleas throughout 2024 and 2025. These rulings dismantled Bayer’s defense that the litigation risk was “unforeseeable” at the time of the merger.

The McKivison verdict, which originally included $2 billion in punitive damages, forced Bayer to fundamentally recalculate its litigation reserves. In February 2026, citing these “continued adverse judgments,” Bayer increased its total litigation provisions to €11. 8 billion. This financial restatement serves as a serious data point for the Cologne plaintiffs, who that the need of such a massive reserve proves the initial risk assessments were fraudulent.

Supreme Court Appeal: Durnell v. Monsanto

Bayer’s defense in Cologne hinges on a concurrent legal battle in the United States Supreme Court. The Court has granted certiorari in Durnell v. Monsanto, with oral arguments scheduled for April 27, 2026. The central problem is federal preemption: whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) bars state-law failure-to-warn claims when the EPA has approved the product label.

A victory for Bayer in Durnell would theoretically nullify billions in outstanding claims and chance undercut the “gross negligence” narrative in Germany. Conversely, a loss would cement the liability, likely accelerating a settlement in the Cologne proceedings. Legal analysts estimate that a negative ruling could increase Bayer’s total liability exposure by an additional $4 billion to $6 billion, further eroding shareholder equity.

2026 Settlement Framework and Cash Flow Impact

In a move to contain the before the Supreme Court rules, Bayer announced a $7. 25 billion global settlement method in February 2026. This structure is designed to resolve approximately 58, 000 pending claims and future cases over a 21-year period. The immediate financial consequence is severe: Bayer projects a negative free cash flow for fiscal year 2026, driven by €5 billion in upfront litigation payouts.

“The settlement buys Bayer time, without a win in the Supreme Court, a new wave of lawsuits could roll over Bayer in a few years. The Cologne court view this payout as a retroactive admission of the risk magnitude.”
, Ingo Speich, Deka Investment (Shareholder Statement, Feb 2026)

Future Claim Management: The Dormant Case Inventory Strategy

By March 2026, Bayer AG faced a serious logistical reality: even with settling nearly 100, 000 claims in the initial 2020 sweeping agreements, a stubborn “long tail” of litigation had metastasized into a new emergency. This “dormant case inventory”, comprising approximately 67, 000 unsettled cases filed primarily in state courts, represented a multi-billion-dollar liability that could no longer be managed through piecemeal trials. The strategy shifted from individual defense to a dual-track method: aggressive liquidation of the backlog via a new global settlement method, simultaneous with a high- Supreme Court appeal intended to sever future liabilities.

The “Containment” Protocol: $7. 25 Billion Liquidation

On February 17, 2026, Bayer executed the of its inventory management strategy by proposing a $7. 25 billion class settlement. Unlike the 2020 agreements, which focused on immediate payouts, this structure was designed as a “declining capped annual payment” system spanning 21 years. The method aimed to resolve the remaining 67, 000 active cases while creating a structured containment vessel for future claims. The timing was precise. The proposal was filed in the Circuit Court of the City of St. Louis just one month after the Supreme Court granted certiorari in *Monsanto Co. v. Durnell*. Legal analysts characterized this as a “liquidation move,” intended to clear the docket of volatile state court cases before the Supreme Court could chance alter the.

The inventory data reveals the of the backlog that forced this decision:

The “Durnell” Hedge: Preemption as a Kill Switch

While the $7. 25 billion settlement addressed the *past* and *present* inventory, the *Durnell* appeal served as the strategic hedge for the *future*. Bayer’s legal team operated on the premise that a favorable Supreme Court ruling on federal preemption would nullify the claims of any plaintiffs who opted out of the settlement. This “squeeze” tactic was designed to force holdout plaintiffs into the settlement. If they refused the payout and waited for trial, they risked their entire case being dismissed if the Supreme Court ruled that the EPA’s label approval preempted state failure-to-warn claims.

“This is a choice for speed and containment over a protracted legal battle. A decision in our favor [in Durnell] would address cases not covered by the settlement, including significant adverse pending judgments.”
, Bill Anderson, CEO of Bayer AG (February 17, 2026)

Philadelphia’s Role in Forcing Liquidation

The urgency to liquidate the dormant inventory was driven directly by the failure of the “wait-and-see” strategy in Philadelphia. The Philadelphia Court of Common Pleas (PCCP) had become a major liability engine, producing the $2. 25 billion *McKivison* verdict and the $78 million *Melissen* verdict in 2024. Unlike federal courts, which frequently stayed cases pending MDL developments, the PCCP continued to schedule trials. This “docket pressure” meant that Bayer could not simply wait for the Supreme Court; the cost of holding the inventory had become too high. Every month the dormant cases sat in the Philadelphia queue increased the probability of another “nuclear verdict,” forcing Bayer to increase its reserves by billions.

Financial Toll: The Cost of Closure

The execution of this strategy exacted a severe toll on Bayer’s balance sheet. In February 2026, the company announced it had increased its litigation provisions from €7. 8 billion to €11. 8 billion (approximately $12. 8 billion USD) to cover the new settlement and remaining defense costs. CFO Wolfgang Nickl confirmed that the company expected a negative free cash flow for fiscal year 2026, driven by an estimated €5 billion in litigation payouts scheduled for that year alone. To finance this massive liquidity event, Bayer secured an $8 billion loan facility, signaling that the company was leveraging its future earnings to buy its way out of the Roundup legacy once and for all.

The “Texas Two-Step” method: A Legal Dead End

For nearly a decade, the “Texas Two-Step” divisional merger strategy stood as the theoretical “nuclear option” for corporations facing existential mass tort liabilities. The maneuver involves utilizing Texas Business Organizations Code (specifically Section 10. 001) to execute a divisive merger, splitting a solvent parent company into two new entities: “BadCo,” which assumes the mass tort liabilities and minimal assets, and “GoodCo,” which retains the operating assets and immunity. “BadCo” then immediately files for Chapter 11 bankruptcy, halting all litigation through the automatic stay while “GoodCo” continues business as usual.

For Bayer AG, facing over 50, 000 pending Roundup claims in 2024 and 2025, this strategy represented a chance firewall against the billion-dollar verdicts emerging from Philadelphia and Missouri. yet, the legal viability of this method collapsed before Bayer could deploy it. The strategy’s failure is not due to a absence of execution by Bayer, rather the establishment of a hostile judicial blockade by the United States Court of Appeals for the Third Circuit, the very jurisdiction governing the serious federal multidistrict litigation and the Philadelphia Court of Common Pleas.

The J&J Precedent: LTL Management’s Double Dismissal

The decisive blow to the Texas Two-Step as a viable shield for solvent conglomerates was delivered through the failed bankruptcy attempts of Johnson & Johnson’s subsidiary, LTL Management LLC. This precedent removed the bankruptcy exit ramp for Bayer.

In January 2023, the Third Circuit Court of Appeals dismissed LTL Management’s Chapter 11 petition. The court ruled that the filing absence “good faith” because the debtor was not in “financial distress.” J&J had created a funding agreement backstopping LTL with up to $61. 5 billion, rendering the subsidiary solvent by definition.

J&J attempted a second “Two-Step” in 2023, reducing the funding agreement to approximately $30 billion to manufacture an appearance of distress. On July 25, 2024, the Third Circuit affirmed the dismissal of this second attempt (*In re LTL Management, LLC*), solidifying a legal standard that makes it nearly impossible for a solvent parent like Bayer to isolate liabilities without exposing its core assets to fraudulent transfer claims.

Third Circuit Ruling (2024): “Good intentions, such as to protect the brand or detailed resolve litigation, do not suffice alone. What counts to access the Bankruptcy Code’s safe harbor is to meet its intended purposes. Only a putative debtor in financial distress can do so.”

The “Financial Distress” Catch-22

The Third Circuit’s rulings created a “Catch-22” for Bayer. To qualify for bankruptcy protection under the new precedent, a subsidiary like “Monsanto BadCo” would need to be genuinely financially distressed. yet, if Bayer AG (the parent) failed to provide a funding agreement, it would face immediate lawsuits for fraudulent transfer, accusing the company of stripping assets to defraud creditors. If Bayer did provide the funding to avoid fraud claims, the subsidiary would be deemed solvent and ineligible for bankruptcy.

This legal reality forced Bayer CEO Bill Anderson to abandon the bankruptcy route in late 2025, pivoting instead to the $7. 25 billion settlement method announced in February 2026. The table outlines the comparative failure of the Two-Step strategy across major mass tort defendants.

Comparative Analysis: The Failure of the Divisional Merger Strategy

The 3M Parallel: Aearo Technologies

Bayer’s legal team also scrutinized the failure of 3M’s attempt to use the Two-Step for its combat earplug litigation. In that case, 3M placed its subsidiary, Aearo Technologies, into bankruptcy in Indianapolis. The bankruptcy court refused to extend the automatic stay to the non-bankrupt parent (3M), rendering the filing useless as a litigation shield.

For Bayer, this signaled that even if they filed for bankruptcy outside the hostile Third Circuit, judges were increasingly unwilling to protect the solvent parent company. With the McKivison and Melissen verdicts in Philadelphia proving that juries could pierce corporate veils, the bankruptcy option transformed from a strategic shield into a liability trap that could trigger a shareholder revolt and credit rating downgrade.

Strategic Pivot to Settlement

By early 2025, credit rating agencies had warned that a failed bankruptcy attempt could result in a “negative outlook” or downgrade for Bayer’s debt. The uncertainty of the “Two-Step” contrasted poorly with the definitive, albeit expensive, nature of a settlement.

Consequently, the “failed precedent” of the Texas Two-Step directly necessitated the $7. 25 billion settlement structure Bayer announced on February 17, 2026. Without the use of a bankruptcy threat, Bayer was forced to negotiate a consensual resolution while pinning its remaining hopes on the Durnell Supreme Court appeal to limit future liabilities.

June 2026 Scenario Planning: Preemption Ruling

As the United States Supreme Court method the end of its term in June 2026, Bayer AG faces a binary legal event that determine the solvency of its Crop Science division. The Court’s decision in Monsanto Co. v. Durnell (Docket No. 24-1068) serves as the terminal junction for the circuit split created by the Third Circuit’s 2024 Schaffner ruling. For Bayer, the ruling represents the difference between a definitive end to the Roundup litigation and a chance financial collapse driven by uncapped state-tort liabilities.

The Legal Binary: Schaffner vs. Hardeman Standards

The core adjudication rests on whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state law failure-to-warn claims. The Supreme Court must choose between two incompatible appellate standards that have bifurcated the federal judiciary since August 2024.

Scenario A: Preemption Affirmed (The Bull Case)

If the Supreme Court affirms the Schaffner standard, the legal basis for the Philadelphia Court of Common Pleas verdicts evaporates. The $400 million judgment in McKivison and the $78 million award in Melissen rely on the premise that Monsanto had a duty under Pennsylvania law to warn users of carcinogenic risks, a duty the Third Circuit explicitly ruled was preempted by federal law.

Under this scenario, Bayer’s litigation provisions, which stood at $7. 6 billion (€6. 5 billion) as of September 30, 2025, would largely be released back into the company’s equity. The 54, 000 active cases remaining in the U. S. docket would face immediate dismissal motions. Legal analysts project that a pro-preemption ruling would trigger a reversal of the Caranci verdict ($175 million), which the Pennsylvania Superior Court affirmed in May 2025, as the federal preemption doctrine would supersede the state appellate court’s interpretation.

Scenario B: Preemption Rejected (The Bear Case)

A ruling upholding the Hardeman standard would cement the “parallel requirements” doctrine, ruling that the EPA’s approval of the Roundup label does not shield Bayer from state juries. This outcome would validate the Philadelphia mass tort strategy, where plaintiffs have successfully argued that Bayer’s conduct was “reprehensible” even with federal regulatory compliance.

The financial of this scenario are severe. With 65, 000 unresolved claims as of late 2025, a rejection of preemption would force Bayer to calculate settlements based on the Philadelphia verdict averages. Even using a conservative settlement value derived from the 2020 agreements, the liability could exceed the existing $7. 6 billion provision by a factor of three. CEO Bill Anderson’s May 2024 characterization of the litigation as an “existential threat” would materialize, likely forcing the company to consider structural separation of the Crop Science division or aggressive bankruptcy protection maneuvers similar to the “Texas Two-Step” strategy attempted by other conglomerates.

Financial Exposure and Provision Adequacy

Bayer’s Q3 2025 financial report highlights the precarious nature of its current reserves. The company allocated an additional $1. 37 billion to litigation provisions in August 2025, responding to the adverse appellate rulings in Missouri and Pennsylvania. yet, these reserves assume a “containment” strategy rather than a total defense failure.

“The current provision of $7. 6 billion assumes a rational settlement framework. It does not account for a scenario where the Supreme Court validates the Philadelphia punitive damages model across all 50 states.” , Bayer AG Q3 2025 Investor Briefing Note

The between the provision and the chance exposure is clear. The McKivison verdict alone, even after remittitur to $400 million, represents 5. 2% of the total remaining provision. If the Supreme Court denies preemption, the “Philadelphia Premium”, the tendency for juries in that jurisdiction to award massive punitive damages, could become the national baseline for settlement negotiations.

The Settlement Pressure Cooker

The months leading up to June 2026 present a tactical dilemma. Bayer must decide whether to negotiate a global settlement before the ruling to hedge against a total loss, or wait for the verdict. Historical data suggests the cost of settlement rises as the plaintiff bar senses weakness. Following the Schaffner ruling in August 2024, Bayer’s stock jumped 11%, signaling market confidence in the preemption defense. Conversely, the Melissen verdict in October 2024 caused a 4% contraction, illustrating the market’s sensitivity to the Philadelphia docket.

As of December 2025, the Solicitor General’s office had weighed in favoring the review, citing the need to resolve the circuit split. This intervention historically correlates with a higher probability of reversal, yet the conservative majority of the Court has shown inconsistent deference to federal agencies like the EPA. The June 2026 decision not resolve a legal argument; it dictate whether Bayer AG continues as an integrated life sciences giant or is dismantled by the weight of American tort law.

The Atlantic Schism: Regulatory Science vs. Tort Liability

As of March 2026, Bayer AG operates in two distinct legal realities separated by the Atlantic Ocean. In the European Union, the company’s glyphosate franchise is secured by a ten-year regulatory shield, anchored in exhaustive scientific reviews by the continent’s highest safety authorities. In the United States, even with identical chemical compositions and similar federal regulatory findings, the company faces a volatile liability driven by state tort litigation and billion-dollar jury verdicts. This trans-Atlantic exposes the fundamental friction between technocratic risk assessment and the American civil justice system.

The European: The 2023 Renewal

The foundation of Bayer’s European stability was laid on November 29, 2023, when the European Commission adopted Implementing Regulation (EU) 2023/2660, renewing the approval of glyphosate for ten years, until December 15, 2033. This decision, while politically contentious, was legally grounded in the rigorous findings of the European Food Safety Authority (EFSA) and the European Chemicals Agency (ECHA).

The scientific consensus supporting this renewal was explicit:

• ECHA (May 2022): The Committee for Risk Assessment (RAC) concluded that classifying glyphosate as a carcinogen was “not justified,” maintaining its classification only as causing serious eye damage and being toxic to aquatic life.
• EFSA (July 2023): After reviewing 2, 400 studies and 180, 000 pages of data, EFSA identified “no serious areas of concern” regarding human or animal health that would preclude approval.

Unlike the U. S. system, where lay juries adjudicate scientific disputes, the EU model relies on centralized expert review. When Member States failed to reach a qualified majority in the Appeal Committee on November 16, 2023, the Commission exercised its legal obligation to adopt the renewal based on these safety assessments. This unilateral action insulated Bayer from “failure to warn” liability in Europe, as EU labeling laws strictly adhere to the ECHA hazard classifications, which do not include cancer.

The American Anomaly: Liability Without Toxicity

In clear contrast, the United States regulatory environment presents a paradox. The U. S. Environmental Protection Agency (EPA) has consistently maintained that glyphosate is “not likely to be carcinogenic to humans,” a stance reaffirmed during its registration review process. yet, the U. S. legal system permits state tort claims to proceed on the theory that the product is “misbranded” for absence a cancer warning, a warning the EPA has explicitly prohibited as false and misleading.

This regulatory-legal disconnect fueled the financial shocks of 2024 and 2025, including the $2. 25 billion McKivison verdict in Philadelphia. While the EU’s regulatory approval acts as a pre-emptive shield against such claims, the U. S. EPA’s approval has, until chance, functioned only as a rebuttable defense in state courts. The result is a “patchwork” liability map where a federally approved product carries catastrophic financial risk in specific jurisdictions like the Philadelphia Court of Common Pleas.

2026 Strategic Convergence: The Durnell Brief

Bayer’s legal strategy in 2026 explicitly use this global. In its brief for Monsanto Co. v. Durnell (Docket No. 24-1068), following the Supreme Court’s certiorari grant on January 16, 2026, the defense that the “global consensus” of regulatory bodies, including the EU, Canada, Japan, and Australia, renders the state-law requirement for a cancer warning not just scientifically baseless, legally preempted.

“The between the scientific findings of the world’s most rigorous regulators and the verdicts of state juries has created an untenable compliance trap. A manufacturer cannot simultaneously obey the EPA’s prohibition on false warnings and a state jury’s demand for them.”

The Durnell appeal seeks to import the “regulatory primacy” model of the EU into U. S. jurisprudence via the Supremacy Clause. If the Supreme Court rules in Bayer’s favor, it would align the U. S. liability standard with the EU’s regulatory standard, closing the gap that has cost the company billions.

Financial of the Divide

The cost of this regulatory is quantifiable in Bayer’s 2026 financial provisions. While the European market generates stable revenue with minimal litigation costs, the U. S. market massive liquidity reserves. On February 17, 2026, Bayer announced a proposed $7. 25 billion class settlement to resolve future U. S. claims, a direct financial consequence of the U. S. tort system’s refusal to defer to regulatory science.

Ongoing Challenges in Europe

While the EU offers regulatory stability, it is not devoid of legal friction. NGOs, including Pesticide Action Network (PAN) Europe, filed suit in the EU General Court challenging the 2023 renewal. yet, unlike U. S. tort cases which seek damages for personal injury, these European actions seek administrative annulment of the approval. Bayer formally joined these proceedings in late 2025 to defend the Commission’s decision. Crucially, these challenges do not generate the multi-million dollar compensatory awards seen in Philadelphia, keeping the financial risk contained to market access rather than balance sheet.

Conclusion: The Supreme Court as the Final Arbiter

The global regulatory on glyphosate has forced Bayer to operate two contradictory business models: a science-based agricultural partner in Europe and a litigation-defense operation in the United States. The Supreme Court’s upcoming decision in Durnell represents the final attempt to harmonize these realities. A ruling for preemption would validate the global regulatory consensus and end the “Philadelphia anomaly,” while a ruling against it would cement the U. S. as a permanent outlier in global chemical liability.